Trials / NCT05921162
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
Enrolling by invitation Observational Natural history / observational
- Sponsor
- Nanoscope Therapeutics Inc.
- Treatment
- Gene Therapy product:vMCO-I
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa, Retinal Disease, Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 11 participants
- Started
- 2023-07-14
- Main results expected
- 2025-05
- Results posted
- Not yet
- Record last updated
- 2025-03-25
What the study is testing
This study "A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection" is an observational study and will be conducted following Good Clinical Practice (GCP)- International Conference on Harmonization (ICH) guidelines. Eligible subjects satisfying all inclusion and none of the exclusion criteria will be enrolled. All subject who completed the parent clinical study (NSCT/CT/18/01) will undergo safety and efficacy assessments up to 5 years post study drug injection
Where it runs
India (1)
- JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack, Odisha